Edwards Lifesciences (NYSE:EW) Price Target Raised to $110.00 at Citigroup

Edwards Lifesciences (NYSE:EW) had its target price raised by Citigroup from $101.00 to $110.00 in a research note issued to investors on Wednesday, Marketbeat reports. They currently have a buy rating on the medical research company’s stock.

A number of other research firms have also issued reports on EW. Truist Financial set a $90.00 price target on shares of Edwards Lifesciences and gave the company a “hold” rating in a report on Friday, April 24th. Wall Street Zen lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Wolfe Research upgraded shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price objective on the stock in a research report on Wednesday, April 1st. BTIG Research lifted their target price on Edwards Lifesciences from $100.00 to $110.00 and gave the company a “buy” rating in a research note on Tuesday, June 30th. Finally, Robert W. Baird upped their target price on Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a report on Friday, April 24th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $97.09.

Edwards Lifesciences Stock Down 1.2%

Shares of EW stock opened at $93.64 on Wednesday. Edwards Lifesciences has a 1 year low of $72.30 and a 1 year high of $96.29. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42. The stock has a market cap of $53.92 billion, a PE ratio of 49.81, a price-to-earnings-growth ratio of 2.38 and a beta of 0.86. The business’s fifty day moving average is $86.33 and its 200-day moving average is $83.77.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The company had revenue of $1.65 billion for the quarter, compared to analysts’ expectations of $1.60 billion. During the same quarter in the previous year, the company posted $0.64 EPS. The business’s revenue was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Equities analysts expect that Edwards Lifesciences will post 3 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, VP Donald E. Bobo, Jr. sold 23,145 shares of the business’s stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total value of $2,000,190.90. Following the completion of the sale, the vice president directly owned 98,611 shares in the company, valued at approximately $8,521,962.62. The trade was a 19.01% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Daniel J. Lippis sold 619 shares of the company’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $91.40, for a total value of $56,576.60. Following the sale, the vice president directly owned 40,411 shares of the company’s stock, valued at $3,693,565.40. The trade was a 1.51% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 44,958 shares of company stock valued at $3,798,764 over the last quarter. Insiders own 0.31% of the company’s stock.

Institutional Trading of Edwards Lifesciences

A number of hedge funds have recently modified their holdings of the company. Hanson & Doremus Investment Management bought a new position in Edwards Lifesciences during the 1st quarter valued at about $25,000. JPL Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences during the third quarter worth approximately $25,000. MV Capital Management Inc. acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth approximately $26,000. RMG Wealth Management LLC bought a new position in shares of Edwards Lifesciences in the first quarter valued at approximately $26,000. Finally, Kemnay Advisory Services Inc. acquired a new position in shares of Edwards Lifesciences in the 4th quarter worth approximately $27,000. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.